IndustryCompany release

Gedeon Richter licenses estetrol combination rights to Eli Lilly in worldwide deal

Gedeon Richter · Thu 12 Nov 2026

Lilly gains exclusive rights to develop estetrol combinations in women's health and cardiometabolic disease, plus a US co-commercialisation option on Richter's FYLREVY, and will buy about $15M of Richter shares.

Gedeon Richter announced on 12 November 2026 that it has granted Eli Lilly an exclusive worldwide licence to develop and commercialise combinations of estetrol (E4) with Lilly compounds. The licence covers women's health and cardiometabolic diseases.

The agreement also gives Lilly an option to co-commercialise Richter's E4 monotherapy in the US. That product, FYLREVY, is approved in the European Economic Area for hormone replacement therapy (HRT) and is under review by the US Food and Drug Administration for menopausal vasomotor symptoms.

Richter is eligible to receive milestone payments and royalties. Lilly will also purchase about USD 15 million of Richter treasury shares. The announcement as summarised does not give figures for the milestones or royalty rates.

Closing is subject to clearance under the US Hart-Scott-Rodino Act and other customary conditions. As general context, HSR review is the US antitrust pre-merger notification process, which can apply to licensing and equity transactions of this kind.

What it means for your team

  • Teams tracking FYLREVY should note the pending FDA review for menopausal vasomotor symptoms; the US co-commercialisation option is tied to that product's US prospects.
  • Combination products pairing E4 with Lilly compounds would be new development programmes, so regulatory strategy and safety-data plans for those combinations are still to be defined.
  • Market-access teams should watch for closing, which depends on HSR clearance and other conditions, before assuming the licence and option are in effect.

Company's press release: Gedeon Richter ↗

Article written by VigiEye from the official source (Gedeon Richter). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →